sales@debyesci.com
|
00852-2521-1836
Structure Search

Product

WE ONLY MAKE FINE PRODUCTS

Thalidomide

Catalog_Number:

DB-051759

CAS:

50-35-1

Formula:

C13H10N2O4

Formula_Weight:

258.233g/mol

Purity:

95%
NOTICE: THE PRODUCT IS JUST ONLY FOR LAB RESEARCH, NOT FOR OTHER USE.
IUPAC_Name: 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
InChI InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)
InChiKey UEJJHQNACJXSKW-UHFFFAOYSA-N
Synonyms:

1H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3-piperidinyl)-

2-(2,6-Dioxo-3-piperidinyl)-1H-isoindol-1,3(2H)-dion

2-(2,6-Dioxo-3-pipéridinyl)-1H-isoindole-1,3(2H)-dione

Canonical SMILES: C1CC(=O)NC(=O)C1N2C(=O)C3=CC=CC=C3C2=O
Physical Description:

PHYSICAL DESCRIPTION: Needles or white powder. (NTP, 1992)

Needles:O'Neil, M.J. (ed.). The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals. Cambridge, UK: Royal Society of Chemistry, 2013., p. 1716

Boiling Point: 509.7±43.0 °C at 760 mmHg
Melting Point: 516 to 520° F (NTP, 1992)
Flash Point: 262.1±28.2 °C
Solubility: less than 1 mg/mL at 72° F (NTP, 1992)
Stability: Stable under recommended storage conditions.
Density: 1.5±0.1 g/cm3
Vapour Pressure: 0.0±1.3 mmHg at 25°C
Enthalpy of Vaporization: 78.0±3.0 kJ/mol
Index of Refraction: 1.646
Molar Refractivity: 62.4±0.3 cm3
Experimental Solubility: DMSO
Appearance: Not Available
Vapor Pressure: 2.05X10-14 mm Hg at 25 deg C (est)
Storage Conditions: Commercially available thalidomide capsules should be stored at 15-30 deg C and protected from light.
Decomposition: When heated to decomposition it emits toxic fumes of /nitrogen oxides/.
Reactive Group: Amides and Imides
Synthesis Reference: Jamshed Shah, "Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs." U.S. Patent US20030139451, issued July 24, 2003.
Drug Indication: For the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). Also for use as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence.
Safety: 20/21/22
Health Hazard: SYMPTOMS: Symptoms of exposure to this compound include peripheral neuritis, numbness, paresthesias in the extremities and signs of motor neuron disease. Other symptoms include teratogenic effects and peripheral neuropathy. Exposure to this type of compound may lead to sleepiness, mental confusion, unsteadiness, coma with slow, shallow respiration, flaccid muscles, cyanosis, hypotension, hypothermia or hyperthermia, absent reflexes, pulmonary edema, atelectasis or aspiration pneumonia with signs of lung consolidation and fever, acidosis and fetal injury. Death occurs most often from pneumonia, pulmonary edema or refractory hypotension. ACUTE/CHRONIC HAZARDS: When heated to decomposition this compound emits toxic fumes of nitrogen oxides. (NTP, 1992)
Fire Hazard: Flash point data for this chemical are not available; however, it is probably combustible. (NTP, 1992)
GHS Classification:
Signal: Danger
GHS Hazard Statements
Aggregated GHS information provided by 75 companies from 7 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

H302 (93.33%): Harmful if swallowed [Warning Acute toxicity, oral]
H360 (96%): May damage fertility or the unborn child [Danger Reproductive toxicity]

Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.

Precautionary Statement Codes
P201, P202, P264, P270, P281, P301+P312, P308+P313, P330, P405, and P501
Air and Water Reactions: Insoluble in water.
Call It